Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
US FDA’s Vinay Prasad, Controversial CBER Director, Leaving In April
Mar 06 2026
•
By
Derrick Gingery
Vinay Prasad, right, will leave the FDA in late April.
(FDA webcast)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
More from US FDA
More from United States